Showing 1 - 2 results of 2 for search 'Joseph Burgents', query time: 0.02s Refine Results
  1. 1
    346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

    346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by Christian Poehlein, Joseph Burgents, Christian Gratzke, Cuizhen Niu

    Published 2020-11-01
    Article
  2. 2
    344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

    344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641) by Arnulf Stenzl, Julie Nicole Graff, Joseph Burgents, Li Wen Liang

    Published 2020-11-01
    Article

Search Tools: